治疗药物对富亮氨酸α -2糖蛋白监测内镜缓解溃疡性结肠炎的影响。

Junnosuke Hayasaka, Akira Matsui, Daisuke Kikuchi, Shu Hoteya
{"title":"治疗药物对富亮氨酸α -2糖蛋白监测内镜缓解溃疡性结肠炎的影响。","authors":"Junnosuke Hayasaka, Akira Matsui, Daisuke Kikuchi, Shu Hoteya","doi":"10.1159/000547007","DOIUrl":null,"url":null,"abstract":"<p><p>Background Serum leucine-rich alpha-2 glycoprotein (LRG) levels are measured to monitor ulcerative colitis (UC); however, the impact of concomitant medications on LRG remains unclear. This exploratory study aimed to determine the effects of various agents on serum LRG levels. Methods We conducted a single-center, retrospective study using medical records at our hospital from October 1, 2020, to June 30, 2023. Patients who underwent lower gastrointestinal endoscopy within 1 year before or after LRG measurement and had confirmed mucosal healing were included. The effects of medication on LRG levels were assessed using multiple regression analysis following multiple imputations. The analyzed agents included 5-aminosalicylic acid (5-ASA), immunomodulators, corticosteroids, calcineurin inhibitors, Janus kinase inhibitors, vedolizumab, interleukin-23 receptor antagonists, and anti-TNF-α agents. Results A total of 214 patients (351 measurements) were included. The median LRG was 11.2 μg/ml. Among patients, 63.2 had a Mayo Endoscopic Subscore of 0, while 36.8% had a score of 1. The frequency of medication use was as follows: 5-ASA (88.9%), immunomodulators (13.1%), corticosteroids (2.6%), calcineurin inhibitors (0.9%), Janus kinase inhibitors (5.7%), vedolizumab (3.4%), interleukin-23 receptor antagonists (1.7%), and anti-TNF-α agents (7.4%). Corticosteroids, calcineurin inhibitors, Janus kinase inhibitors, and anti-TNF-α agents were negatively associated with LRG (β = -3.42, -10.4, -2.34, and -3.01, respectively). Conversely, vedolizumab and interleukin-23 receptor antagonists were positively associated with LRG. (β =1.83 and 4.69, respectively). Conclusions LRG levels are influenced by medications, even in patients with mucosal healing. These effects should be considered when using LRG to monitor UC.</p>","PeriodicalId":520605,"journal":{"name":"Digestive diseases (Basel, Switzerland)","volume":" ","pages":"1-22"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of therapeutic agents on serum leucine-rich alpha-2 glycoprotein for monitoring endoscopically remitted ulcerative colitis.\",\"authors\":\"Junnosuke Hayasaka, Akira Matsui, Daisuke Kikuchi, Shu Hoteya\",\"doi\":\"10.1159/000547007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Background Serum leucine-rich alpha-2 glycoprotein (LRG) levels are measured to monitor ulcerative colitis (UC); however, the impact of concomitant medications on LRG remains unclear. This exploratory study aimed to determine the effects of various agents on serum LRG levels. Methods We conducted a single-center, retrospective study using medical records at our hospital from October 1, 2020, to June 30, 2023. Patients who underwent lower gastrointestinal endoscopy within 1 year before or after LRG measurement and had confirmed mucosal healing were included. The effects of medication on LRG levels were assessed using multiple regression analysis following multiple imputations. The analyzed agents included 5-aminosalicylic acid (5-ASA), immunomodulators, corticosteroids, calcineurin inhibitors, Janus kinase inhibitors, vedolizumab, interleukin-23 receptor antagonists, and anti-TNF-α agents. Results A total of 214 patients (351 measurements) were included. The median LRG was 11.2 μg/ml. Among patients, 63.2 had a Mayo Endoscopic Subscore of 0, while 36.8% had a score of 1. The frequency of medication use was as follows: 5-ASA (88.9%), immunomodulators (13.1%), corticosteroids (2.6%), calcineurin inhibitors (0.9%), Janus kinase inhibitors (5.7%), vedolizumab (3.4%), interleukin-23 receptor antagonists (1.7%), and anti-TNF-α agents (7.4%). Corticosteroids, calcineurin inhibitors, Janus kinase inhibitors, and anti-TNF-α agents were negatively associated with LRG (β = -3.42, -10.4, -2.34, and -3.01, respectively). Conversely, vedolizumab and interleukin-23 receptor antagonists were positively associated with LRG. (β =1.83 and 4.69, respectively). Conclusions LRG levels are influenced by medications, even in patients with mucosal healing. These effects should be considered when using LRG to monitor UC.</p>\",\"PeriodicalId\":520605,\"journal\":{\"name\":\"Digestive diseases (Basel, Switzerland)\",\"volume\":\" \",\"pages\":\"1-22\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Digestive diseases (Basel, Switzerland)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000547007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digestive diseases (Basel, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000547007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:检测血清富含亮氨酸α -2糖蛋白(LRG)水平以监测溃疡性结肠炎(UC);然而,合用药物对LRG的影响尚不清楚。本探索性研究旨在确定各种药物对血清LRG水平的影响。方法采用2020年10月1日至2023年6月30日在我院进行的单中心回顾性研究。在LRG测量前后1年内接受下消化道内窥镜检查并确认粘膜愈合的患者纳入研究。用药对LRG水平的影响采用多重归算后的多元回归分析进行评估。分析的药物包括5-氨基水杨酸(5-ASA)、免疫调节剂、皮质类固醇、钙调磷酸酶抑制剂、Janus激酶抑制剂、维多单抗、白介素-23受体拮抗剂和抗tnf -α药物。结果共纳入214例患者(351次测量)。中位LRG为11.2 μg/ml。63.2例患者梅奥内镜亚评分为0分,36.8%的患者梅奥内镜亚评分为1分。用药频次依次为:5-ASA(88.9%)、免疫调节剂(13.1%)、皮质类固醇(2.6%)、钙调磷酸酶抑制剂(0.9%)、Janus激酶抑制剂(5.7%)、维多单抗(3.4%)、白介素-23受体拮抗剂(1.7%)、抗tnf -α药物(7.4%)。皮质类固醇、钙调磷酸酶抑制剂、Janus激酶抑制剂和抗tnf -α药物与LRG呈负相关(β分别为-3.42、-10.4、-2.34和-3.01)。相反,vedolizumab和白细胞介素-23受体拮抗剂与LRG呈正相关。(β分别=1.83和4.69)。结论LRG水平受药物影响,即使在粘膜愈合的患者中也是如此。在使用LRG监测UC时应考虑这些影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Impact of therapeutic agents on serum leucine-rich alpha-2 glycoprotein for monitoring endoscopically remitted ulcerative colitis.

Background Serum leucine-rich alpha-2 glycoprotein (LRG) levels are measured to monitor ulcerative colitis (UC); however, the impact of concomitant medications on LRG remains unclear. This exploratory study aimed to determine the effects of various agents on serum LRG levels. Methods We conducted a single-center, retrospective study using medical records at our hospital from October 1, 2020, to June 30, 2023. Patients who underwent lower gastrointestinal endoscopy within 1 year before or after LRG measurement and had confirmed mucosal healing were included. The effects of medication on LRG levels were assessed using multiple regression analysis following multiple imputations. The analyzed agents included 5-aminosalicylic acid (5-ASA), immunomodulators, corticosteroids, calcineurin inhibitors, Janus kinase inhibitors, vedolizumab, interleukin-23 receptor antagonists, and anti-TNF-α agents. Results A total of 214 patients (351 measurements) were included. The median LRG was 11.2 μg/ml. Among patients, 63.2 had a Mayo Endoscopic Subscore of 0, while 36.8% had a score of 1. The frequency of medication use was as follows: 5-ASA (88.9%), immunomodulators (13.1%), corticosteroids (2.6%), calcineurin inhibitors (0.9%), Janus kinase inhibitors (5.7%), vedolizumab (3.4%), interleukin-23 receptor antagonists (1.7%), and anti-TNF-α agents (7.4%). Corticosteroids, calcineurin inhibitors, Janus kinase inhibitors, and anti-TNF-α agents were negatively associated with LRG (β = -3.42, -10.4, -2.34, and -3.01, respectively). Conversely, vedolizumab and interleukin-23 receptor antagonists were positively associated with LRG. (β =1.83 and 4.69, respectively). Conclusions LRG levels are influenced by medications, even in patients with mucosal healing. These effects should be considered when using LRG to monitor UC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信